Odanacatib is is novel drug candidate for Cat K receptor inhibition and presently under phase III stage of clinical trial. The present investigation attempted to highlight mechanism of Odanacatib by docking simulation techniques. Docking results divulge that, said drug candidate elicit hydrophobic and hydrogen bonding interaction with Cat K receptor. The hydrophobic nature of Odanacatib enhance affinity towards Cat K wile few functional group like amino group improve selectivity towards Cat K.
Loading....